- Home
- ALZN vs SYRS Comparison
ALZN vs SYRS Comparison
Compare ALZN & SYRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- SYRS
- Stock Information
- Founded
- ALZN 2016
- SYRS 2011
- Country
- ALZN United States
- SYRS United States
- Employees
- ALZN N/A
- SYRS N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- SYRS Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- SYRS Health Care
- Exchange
- ALZN Nasdaq
- SYRS Nasdaq
- Market Cap
- ALZN 6.1M
- SYRS 5.7M
- IPO Year
- ALZN 2021
- SYRS 2016
- Fundamental
- Price
- ALZN $0.96
- SYRS $0.17
- Analyst Decision
- ALZN Strong Buy
- SYRS Hold
- Analyst Count
- ALZN 1
- SYRS 5
- Target Price
- ALZN $32.00
- SYRS $3.00
- AVG Volume (30 Days)
- ALZN 825.5K
- SYRS 1.2M
- Earning Date
- ALZN 03-24-2025
- SYRS 03-26-2025
- Dividend Yield
- ALZN N/A
- SYRS N/A
- EPS Growth
- ALZN N/A
- SYRS N/A
- EPS
- ALZN N/A
- SYRS N/A
- Revenue
- ALZN N/A
- SYRS $386,000.00
- Revenue This Year
- ALZN N/A
- SYRS N/A
- Revenue Next Year
- ALZN N/A
- SYRS N/A
- P/E Ratio
- ALZN N/A
- SYRS N/A
- Revenue Growth
- ALZN N/A
- SYRS N/A
- 52 Week Low
- ALZN $0.92
- SYRS $0.16
- 52 Week High
- ALZN $15.06
- SYRS $7.96
- Technical
- Relative Strength Index (RSI)
- ALZN 26.54
- SYRS 38.78
- Support Level
- ALZN $0.92
- SYRS $0.16
- Resistance Level
- ALZN $1.15
- SYRS $0.20
- Average True Range (ATR)
- ALZN 0.06
- SYRS 0.02
- MACD
- ALZN -0.01
- SYRS 0.01
- Stochastic Oscillator
- ALZN 13.61
- SYRS 35.75
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About SYRS Syros Pharmaceuticals Inc.
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.